Who are Layla Tab.'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pearlium/EffectiCal, Flamboyant 200/12, Flamboyant 125/12.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/layla-tab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Layla Tab. — Competitive Intelligence Brief

Layla Tab. (Layla Tab.) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker/beta blocker combination. Area: Cardiovascular.

marketed Calcium channel blocker/beta blocker combination Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Layla Tab. (Layla Tab.) — Mather's Pharm. Co., Ltd.. Layla Tab is a combination of two medications, a calcium channel blocker and a beta blocker, which work together to lower blood pressure and reduce the workload on the heart.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Layla Tab. TARGET	Layla Tab.	Mather's Pharm. Co., Ltd.	marketed	Calcium channel blocker/beta blocker combination
Pearlium/EffectiCal	Pearlium/EffectiCal	University of Alberta	marketed	Calcium channel blocker/beta blocker combination
Flamboyant 200/12	Flamboyant 200/12	EMS	phase 3	Calcium channel blocker/beta blocker combination
Flamboyant 125/12	Flamboyant 125/12	EMS	phase 3	Calcium channel blocker/beta blocker combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker/beta blocker combination class)

EMS · 2 drugs in this class
Mather's Pharm. Co., Ltd. · 1 drug in this class
University of Alberta · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Layla Tab. — Competitive Intelligence Brief. https://druglandscape.com/ci/layla-tab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab